Asieris showcases Phase III win in treating precancerous cervical lesions
19 Mar 2024
Clinical ResultPhase 3Phase 2ASCOPhase 1
Preview
Source: Pharmaceutical Technology
According to GlobalData, there will be 123,846 cervical cancer cases in the eight major markets (UK, US, France, Germany, Spain, Italy, Japan, and urban China) by 2030. Credit: Ground Picture via Shutterstock.
Asieris Pharmaceuticals has announced positive data indicating the Phase III trial of its cold light photodynamic drug-device combination Cevira (APL-1702) achieved its primary endpoint in participants with cervical high-grade squamous intraepithelial lesions (HSIL).
HSIL are precancerous lesions linked to human papillomavirus (HPV) that can lead to cervical cancer.
The results were presented at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting in San Diego, US, which was held 16-18 March.
The primary endpoint, which evaluated the response rate six months after administering Cevira, showed a statistically significant improvement of 89.4% compared to the placebo group.
See Also:
Dr. Reddy’s Laboratories files patent for 6-substituted pyridazine compounds for treating diseases dependent on SMARCA2/SMARCA4
Preview
Source: Pharmaceutical Technology
The drug also showed an improved clearance rate of high-risk HPV16 and/or HPV18, with a 103.9% increase in the Cevira group compared to placebo. Cevira was developed through Phase I and II clinical trials by Norway-based Photocure ASA, with Asieris gaining commercialisation rights in July 2019.
The Phase III trial (NCT04484415) enrolled 402 HSIL patients, defining the primary endpoint of response as the conversion of cervical epithelial tissue pathology to normal, or the conversion to low-grade squamous intraepithelial lesion (LSIL) while achieving baseline HPV clearance. Long-lasting infection with certain types of HPV, a common sexually transmitted infection, is the main cause of cervical cancer. If left untreated, HPV can be linked to 95% of cervical cancer cases, according to the World Health Organization.
According to a report on GlobalData’s Pharma Intelligence Center, the number of cervical cancer cases in the eight major markets (UK, US, France, Germany, Spain, Italy, Japan, and urban China) will reach 123,846 by 2030.
GlobalData is the parent company of Clinical Trials Arena.
In the announcement accompanying the data, Linda Wu said: “The study not only demonstrates remarkable efficacy but also exhibits a favourable safety profile, offering a new powerful artillery for the national cervical cancer prevention and control system.
“Additionally, we are making significant progress in product development overseas, aiming to bring this innovative treatment to more patients as soon as possible.”
The company also has other cancer candidates in the pipeline. Earlier this year, a Phase II trial of its repurposed antibiotic drug APL-1202 achieved its primary endpoint in participants with muscular invasive bladder cancer (MIBC). The drug is already approved to treat oesophagal squamous cell carcinoma in China and is also being reviewed by the US Food and Drug Administration to treat the same type of cancer.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.